AzTrials
AzTrials

OncologyINDEEDNCT06350968

Implementation of Online Advance Care Planning Tool for (Hemato-)Oncological Patients Within the Cancer Network Concord

An observational study of Oncology and Advance Care Planning, run by Erasmus Medical Center at 1 site in Netherlands.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The aim of this mixed-methods study is to describe both the implementation process and outcomes of the online module Advance Care Plan for (hemato-)oncology patients within the oncology-network CONCORD. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Oncology, Advance Care Planning, Implementation
How many people
30 participants
Where
1 siteNetherlands
Study dates
1 Oct 2023to 31 Dec 2026
How long will I take part?
3 Years
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients diagnosed with all types of (advanced)cancer.

Who may be able to join

  • Cancer
  • Treated by hospital from the CONCORD-network

Who cannot join

  • -

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Joica A.M. Benschop, MSc contact

+31622586583

j.benschop@erasmusmc.nl

Erasmus Medical Center Oldenmenger, PhD contact

+31651072608

w.h.oldenmenger@erasmusmc.nl

Netherlands1 site, 1 recruiting
  • Joica Benschop

    Rotterdam, 3023TB

    Joica Benschop, MSc, +31622586583, j.benschop@erasmusmc.nl

    Wendy Oldenmenger, PhD, +31651072608, w.h.oldenmenger@erasmusmc.nl

    Recruiting

Other trials in Netherlands

About this study

The aim of this mixed-methods study is to describe both the implementation process and outcomes of the online module Advance Care Plan for (hemato-)oncology patients within the oncology-network CONCORD.

The main question is: How is implementation and assurance of the advance care plan in daily care for (hemato-)oncological patients within CONCORD achieved, so that early integration of advance care planning in oncological care takes place and patient preferences are discussed?

Healthcare providers and patients are asked to use the module and share their experiences with it.

Read the detailed description

Design Implementation research with a mixed-method design. Population

The implementation of advance care planning should benefit the care of (hemato-)oncology patients aged 18 years and older during the palliative phase of their illness. The research focuses on:

  • Oncology patients who have been treated in one or more hospitals from the oncology-network CONCORD after their death (quantitative research)
  • Oncology patients treated with palliative intent in one or more hospitals from this network (interviews)
  • Healthcare providers and implementation staff in the relevant hospitals and from the service area (interviews) Goal The aim of this project is to implement advance care planning in (hemato-)oncology patients treated in one of the hospitals within the oncology-network CONCORD , so that personal preferences and treatment agreements lead to an appropriate treatment plan. This is examined through the process of implementation and assurance of advance care planning in oncological care.

MAIN QUESTION: How is implementation and assurance of the online module advance care planning in daily care for (hemato-)oncological patients within the oncology-network CONCORD achieved, so that early integration of advance care planning in oncological care takes place and patient preferences are discussed? Method

Qualitative research:

Description of the initial situation and the context within each institution, but also of general practitioners and patients using the NASSS Framework. Interviews with project leader, project coordinators in each hospital, healthcare providers from 1st, 2nd and 3rd lines, patients and relatives at the start and end of the project (3-5 in each target group per hospital, taking into account the greatest possible degree of diversity in age, gender and background). At the end of the project, the interviews are repeated to gather information about the experiences and lessons learned and the experiences with facilitating and hindering factors. Each interview is transcribed and analyzed using NVivio or Atlas.ti, analysis programs for qualitative data.

Quantitative research:

EHR-research based on anonymized data using a dashboard. A dashboard is being built in each hospital to analyze data from (hemato-)oncological patients who have been treated in the relevant hospital and have died. The dashboard contains demographic and medical data, the use of the proactive care module and medical consumption in the last three months of their lives.

In each of the participating hospitals, the (hemato-)oncological patients who died in the last 3 months of 2022, 2023, 2024 and 2025 are selected and it will be examined to what extent the advance care plan has been completed and what kind of care the patients have received. A 'Health economic analysis' is carried out using the data from the dashboard. On the one hand, this involves the costs of implementing the advance care planning module used. In addition, the dashboard maps medical consumption in the last three months of life (e.g. ICU admissions, ER visits, clinical admissions, etc.). This is translated into the nationally determined costs for this. This is done both before and after implementation has been mapped out among people who have died, making it possible to gain insight into the difference in costs incurred.

Keywords
Advance Care Planning, Oncology
Medical subject headings
Neoplasms

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Implementation outcome

    Fidelity to the tailored implementation of the ACP-tool

    Measured: 3 years

Secondary outcomes (2)
  1. Intervention outcome

    Healthcare use of patients with cancer in last phase of life (number of hospital admissions, ICU admissions, medication use, etc.)

    Measured: 3 years

  2. Implementation outcome

    Number of filled-in ACP-tools in EHR

    Measured: 3 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Apr 2024
  2. Study start1 Oct 2023
  3. Primary completion30 Jun 2026 (estimated)
  4. Study completion31 Dec 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
30 participants (estimated)
Target duration
3 Years
IDs, dates and publications
ClinicalTrials.gov ID
NCT06350968
Sponsor's protocol ID
MEC-2023-0151
Other IDs
10200012110003
Acronym
INDEED
Status last verified
Apr 2024
First submitted
6 Dec 2023
Last updated
8 Apr 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Benschop JAM, Korfage IJ, van der Heide A, van der Padt-Pruijsten A, van der Rijt CCD, Oldenmenger WH. Facilitating advance care planning in oncology: study protocol for the evaluation of a tailored implementation of an advance care planning tool (the INDEED study). BMC Palliat Care. 2026 Aug 14;25(1):323. doi: 10.1186/s12904-026-02285-9.

    PubMed 42920159

Questions about this trial

What is this clinical trial studying?

An observational study of Oncology and Advance Care Planning, run by Erasmus Medical Center at 1 site in Netherlands.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 8 Apr 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Joica A.M. Benschop, MSc (+31622586583, j.benschop@erasmusmc.nl), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Implementation outcome (time frame: 3 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06350968, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Apr 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in